Welcome to our dedicated page for Myriad Genetics news (Ticker: MYGN), a resource for investors and traders seeking the latest updates and insights on Myriad Genetics stock.
Myriad Genetics, Inc. (NASDAQ: MYGN) generates frequent news as a molecular diagnostic testing and precision medicine company. Its announcements often cover financial results, clinical research, product updates, and collaborations that shape how genetic and genomic testing is used in oncology, women’s health, and mental health care.
Investors and clinicians following MYGN news will see regular earnings releases and financial guidance updates, which the company also furnishes on Form 8-K. These updates describe trends in hereditary cancer testing, tumor profiling, prenatal screening, and pharmacogenomics, along with commentary on business performance and strategic priorities.
Scientific and medical conference activity is another major source of news. Myriad Genetics frequently reports new data on tests such as the MyRisk Hereditary Cancer Test, Precise MRD, FirstGene Multiple Prenatal Screen, Prequel Prenatal Screen, Foresight Carrier Screen, and the GeneSight Psychotropic test. Company communications highlight abstracts and posters at meetings like the San Antonio Breast Cancer Symposium and the National Society of Genetic Counselors Annual Conference.
News items also describe collaborations with partners including SOPHiA GENETICS, Clairity, and MagView, focused on areas such as liquid biopsy companion diagnostics and integrated breast cancer risk assessment platforms. Updates on leadership changes, credit facilities, and conference presentations at investor healthcare events are also part of the MYGN news flow.
This page provides a centralized view of these developments so readers can review Myriad Genetics’ latest financial disclosures, research milestones, product enhancements, and partnership announcements in one place.
Myriad Genetics (NASDAQ: MYGN) said its management will participate in two investor healthcare conferences in late 2025. Wolfe Research Healthcare Conference — fireside chat on Nov. 18, 2025 at 1:20 pm ET. Piper Sandler Healthcare Conference — fireside chat on Dec. 2, 2025 at 12:00 pm ET. Both presentations will be available via live audio webcasts in the investor information section at investor.myriad.com.
Myriad Genetics (NASDAQ: MYGN) expanded its MyRisk® Hereditary Cancer Test on Nov 10, 2025 to include genes referenced in NCCN and ASCO guidelines.
The updated MyRisk panel now includes 63 genes covering more than 11 cancer types, and the company says it includes 100% of genes strongly recommended by national oncology guidelines to support treatment decisions, surveillance planning, and family risk assessment.
Results are available via paper requisition, the Myriad patient portal and multiple EMR platforms including EPIC.
Myriad Genetics (NASDAQ: MYGN) will present 11 new research studies at the National Society of Genetic Counselors 44th Annual Conference on Nov. 7–8, 2025, highlighting oncology and reproductive genetic testing advances.
Featured products include MyRisk Hereditary Cancer Test, FirstGene Multiple Prenatal Screen, Prequel Prenatal Screen, and Foresight Carrier Screen. Myriad will exhibit at booth #317 and share poster presentations on topics such as RNA analysis for VUS interpretation, fetal fraction amplification for early cfDNA screening, prenatal cfDNA detecting maternal colorectal cancer, automated FXN repeat detection, and genetics education and recontact workflows.
Myriad Genetics (NASDAQ: MYGN) reported third quarter 2025 results: revenue $205.7M (down 4% YoY, flat ex‑$8.1M headwinds), gross margin 69.9%, GAAP net loss $27.4M (loss per share $0.29) and adjusted EPS $0.00. Third quarter adjusted EBITDA was $10.3M and test volumes rose to 386,000 (+3% YoY), led by hereditary cancer volume +11%.
The company entered a strategic collaboration with SOPHiA GENETICS for liquid biopsy CDx development, closed a $200M term loan in July, and ended the quarter with $145.4M cash. Myriad reiterated full‑year 2025 guidance: Revenue $818–$828M, gross margin 69.5%–70.0%, adjusted EBITDA $27–$33M, adjusted EPS $(0.02)–$0.02.
Myriad Genetics (NASDAQ: MYGN) reported a post-hoc analysis of the PRIME study showing GeneSight-informed treatment produced faster remission and response in major depressive disorder.
The PRIME trial enrolled 1,944 U.S. Veterans. The analysis, published Oct 30, 2025 in Frontiers in Pharmacology, found GeneSight patients were 27% more likely to achieve remission and 21% more likely to experience response at any time during the 24-week study, with benefits persisting through six months. Myriad plans to submit these data to payers to support access to GeneSight.
Myriad Genetics (NASDAQ: MYGN) will release its third quarter 2025 financial results on November 3, 2025 after market close and will host an earnings conference call the same day at 4:30 PM ET. Management will provide a financial overview and business update for Q3 2025.
A live webcast will be available on Myriad’s Investor Relations website at investor.myriad.com. Telephone participants must register to receive a dial-in number and unique PIN. An archived webcast will be posted at investor.myriad.com following the call.
Myriad Genetics (NASDAQ: MYGN) announced on October 14, 2025 that it added the F8 and FXN genes to the Foresight® Carrier Screen Universal Plus Panel. The company said the additions meet its clinical-selection criteria and that testing is processed in its state-of-the-art facility.
The update makes the Foresight Carrier Screen fully compliant with ACMG recommendations. The release notes F8's link to hemophilia A and FXN's link to Friedreich's ataxia and references the FDA's 2023 approval of omaveloxolone for FA in patients aged 16+.
Myriad Genetics (Nasdaq: MYGN) and SOPHiA GENETICS (Nasdaq: SOPH) have announced a strategic collaboration to develop a global liquid biopsy companion diagnostic (CDx) test. The partnership combines Myriad's U.S. laboratory capabilities with SOPHiA GENETICS' network of over 800 institutions across 70+ countries.
The initial focus will be on MSK-ACCESS® powered with SOPHiA DDM™, a liquid biopsy test developed with Memorial Sloan Kettering Cancer Center that detects genomic alterations from blood samples using ctDNA analysis. Myriad will handle U.S. regulatory submissions, while SOPHiA GENETICS will manage international regulatory processes.
Myriad Genetics (NASDAQ: MYGN) announced the publication of clinical data for its Precise MRD test in The Lancet Oncology. The study focused on patients with oligometastatic clear-cell renal cell carcinoma (ccRCC) and demonstrated significant results in detecting circulating tumor DNA (ctDNA).
The Phase 2 trial revealed that 94% of patients had ctDNA levels below 100 ppm at baseline. Patients testing negative with Precise MRD maintained metastasis-directed therapy for a median of 54 months, compared to 27 months for ctDNA-positive patients. Notably, ctDNA-negative patients showed strong survival rates of 94% at two years and 87% at three years.
Myriad Genetics (NASDAQ: MYGN) announced significant findings from a meta-analysis of six prospective controlled studies involving 3,532 adults with major depressive disorder (MDD). The analysis, published in the Journal of Clinical Psychopharmacology, demonstrated that patients whose clinicians had access to GeneSight® Psychotropic test results showed markedly improved outcomes compared to traditional treatment.
The study revealed that patients in the GeneSight arm were 41% more likely to achieve remission and 30% more likely to achieve response compared to treatment as usual (TAU). The company plans to submit this data to payers to increase patient access to the GeneSight test.